CB-ChMF-11
Preeclampsia
Pre-clinicalActive
Key Facts
About Corion Biotech
Corion Biotech is a private, preclinical-stage biotech company founded in 2012 as a spin-off from the University of Turin. It is developing a novel 'Cell Therapy without Cells' platform derived from placental cells, with initial programs targeting preeclampsia and epithelial cancers (ovarian/breast). The company has achieved key regulatory milestones, including Orphan Drug Designation from the EMA for its preeclampsia candidate and positive FDA feedback, and has secured a GMP manufacturing partnership for clinical supply.
View full company profileTherapeutic Areas
Other Preeclampsia Drugs
| Drug | Company | Phase |
|---|---|---|
| Preeclampsia Rapid Test | Chembio Diagnostic Systems | Development |
| DIANEONATAL | Diagenics | Development/Commercial |